BioNTech to Announce Q3 2025 Financials and Business Updates on November 3, 2025

Posted on by

MAINZ, Germany, October 27, 2025 — (Nasdaq: BNTX, “BioNTech” or “the Company”) will release its third-quarter 2025 financial performance on Monday, November 3, 2025. The company will also host a conference call and live webcast at 8:00 a.m. EST (2:00 p.m. CET) on the same day for investors, analysts, and the general public. During the event, BioNTech will discuss its financial results and provide an update on company activities.

To join the live conference call via phone, please register through this . Upon registration, you will receive dial-in numbers and a PIN. It is advisable to register at least one day prior to the call. The presentation slides and audio webcast will be accessible via this .

Slides and the live webcast can also be accessed on the “Events & Presentations” page within the Investor Relations section of BioNTech’s website at . A webcast replay will be available shortly after the call and will be archived on the website for 30 days.

About BioNTech

BioNTech, or Biopharmaceutical New Technologies, is a global immunotherapy company focused on the next generation of medicine, pioneering innovative therapies for cancer and other serious illnesses. BioNTech utilizes a wide range of computational discovery and therapeutic approaches to rapidly develop novel biopharmaceuticals. Its diverse oncology portfolio, which aims to address the complete spectrum of cancer care, includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies like antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T-cell therapies. Leveraging its expertise in mRNA development and in-house manufacturing, BioNTech and its collaborators are researching and developing several mRNA vaccine candidates for various infectious diseases, in addition to its oncology pipeline. BioNTech has partnerships with numerous global pharmaceutical companies, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech (a member of the Roche Group), Genevant, Genmab, MediLink, OncoC4, Pfizer, and Regeneron.

For further details, please visit .

CONTACTS

Investor Relations
Douglas Maffei, PhD

Media Relations
Jasmina Alatovic

 

“`